Cancer is not a single disease. Two patients with the same type of cancer can have tumors with very different genetic and molecular characteristics, and those differences can determine which treatments will work. Understanding these characteristics is the foundation of precision oncology. Through genomic profiling and other molecular tests, doctors can match patients with targeted therapies and immunotherapies that are more likely to be effective, improving outcomes and avoiding unnecessary treatments.

Market Size and Forecast

According to Polaris Market Research, the global cancer/tumor profiling market was valued at USD 14.05 billion in 2025. The market is expected to reach USD 15.57 billion in 2026 and USD 35.46 billion by 2034, growing at a CAGR of 10.83% from 2026 to 2034. Advances in sequencing technology, rising cancer incidence and the growth of targeted therapies are driving this expansion.

What Is Tumor Profiling?

In simple terms, tumor profiling is the process of analyzing a tumor's genetic, protein and molecular features to understand how it grows and how it may respond to treatment. Tests can identify specific gene mutations, gene fusions, copy number changes, protein expression levels and other biomarkers. Comprehensive genomic profiling examines hundreds of genes in a single test, giving oncologists a detailed picture of each patient's cancer. These insights help guide treatment decisions, clinical trial eligibility and monitoring.

Key Market Drivers

Liquid Biopsy

Traditional profiling relies on tissue biopsies, which can be invasive and are not always possible. Liquid biopsy offers a minimally invasive alternative by analyzing circulating tumor DNA in a blood sample. It enables earlier detection, monitoring of treatment response and tracking of resistance mutations over time. As liquid biopsy technology improves, it is expanding access to profiling for more patients.

Next-Generation Sequencing

Next-generation sequencing (NGS) allows laboratories to analyze many genes simultaneously, quickly and at decreasing cost. This makes broad genomic profiling practical in routine care. NGS supports targeted therapy selection by identifying actionable mutations, helping oncologists choose the right drug for the right patient.

Read More @ https://www.polarismarketresearch.com/industry-analysis/cancer-tumor-profiling-market

Immunotherapy Biomarkers

Immunotherapies such as checkpoint inhibitors have transformed treatment for some cancers, but not all patients respond. Profiling biomarkers such as PD-L1 expression and tumor mutation burden helps identify patients most likely to benefit. As more immunotherapies reach the market, demand for related biomarker testing continues to grow.

Segment Insights

Polaris Market Research segments the market by cancer type, technology, technique and application. By cancer type, breast cancer held the largest share at 29.4% in 2025, reflecting its high incidence and the established role of biomarker testing, such as HER2 and hormone receptor status, in guiding treatment. Lung, colorectal, prostate and other cancers are also major segments.

By technology, next-generation sequencing accounted for the largest share at 38.7% in 2025. Other technologies include polymerase chain reaction (PCR), immunohistochemistry, in situ hybridization and microarrays, each suited to different testing needs.

By technique, genomics held a 46.2% share in 2025, reflecting the central role of DNA and RNA analysis in cancer profiling. Other techniques include proteomics, epigenetics and metabolomics, which are gaining interest as researchers look for a more complete picture of tumor biology.

By application, personalized medicine accounted for 41.5% of the market in 2025. Profiling is also used in diagnostics, prognostics and research, including drug development and clinical trial design.

Regional Analysis

North America led the global cancer/tumor profiling market with a 42.8% share in 2025. Advanced healthcare infrastructure, high adoption of precision medicine, favorable reimbursement for certain genomic tests and the presence of leading diagnostic companies support the region's leadership. Europe is expanding access to genomic testing through national programs, while Asia Pacific is expected to grow quickly as cancer care capabilities expand and sequencing costs fall.

Challenges

The high cost of profiling technologies remains the main restraint on market growth. Reimbursement varies widely across countries and test types, and interpreting complex genomic results requires specialized expertise. Ensuring equitable access to profiling, especially in lower-income regions, is an ongoing challenge.

Competitive Landscape

Key players covered in the Polaris Market Research report include Illumina, Thermo Fisher Scientific, Qiagen, F. Hoffmann-La Roche, Agilent Technologies and Bio-Rad Laboratories. These companies provide sequencing platforms, assays, reagents and software, and many are expanding liquid biopsy and comprehensive profiling offerings through partnerships with laboratories and pharmaceutical companies.

Future Outlook

Cancer/tumor profiling is at the heart of the shift toward personalized cancer care. As sequencing becomes faster and more affordable, liquid biopsy matures and new targeted therapies emerge, profiling will become a routine part of cancer diagnosis and treatment. With the market projected to reach USD 35.46 billion by 2034, diagnostic companies, laboratories and healthcare providers have a significant opportunity to improve patient outcomes through precision oncology.

More Trending Latest Reports By Polaris Market Research:

Multi-access Edge Computing Market Trends

Tacrolimus Market Size

U.S. Metaverse Market Share

Opthalmic Eye Dropper Market Growth

Construction Equipment Market Forecast

Spring Market Analysis

Audience Analytics Market Opportunities

Masterbatch Market Trends

Personal Cooling Device Market Size